Develops and produces specialty chemicals. Offers solutions for the care chemicals market, including ingredients for personal and home care products. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 4% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.9× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
The stock trades 41% below its peak. The market has trimmed its expectations for the company.
It pays out $0.46 per share each year — regular cash for whoever holds the stock.
A loss of $87.8M against $4.6B in annual sales. And on top of that, sales fell from the year before.
Sales are going backwards, not just slowing. Council score: 2/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.